摘要
目的观察吉他西宾单药治疗老年晚期非小细胞肺癌(NSCLC)的疗效和毒性反应。方法对36例Ⅲ～Ⅳ期NSCLC患者采用国产吉西他宾(泽菲)1250mg/m2,静脉注射30min,第1、8天,3～4周重复,2个周期后评价疗效。结果36例均可评价疗效。总有效率(CR+PR)为30.6%(11/36),受益反应63.9%(23/36),中位生存期6.6个月,1年生存率为27.8%,毒副反应以白细胞和血小板下降为常见,但均可耐受。结论吉西他宾单药治疗老年晚NSCLC有较好疗效,可明显改善患者生存质量,延长生存时间,毒性反应轻,患者易于耐受。
Objective To evaluate the clinical effects and toxicities of gemcitabin monotherapy in the treatment of elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods 36 elderly patients with advanced NSCLC received gemcitabin 1：250 mg/m^2 intravenously on day 1 and 8. The chemotherapy was repeated every 3 - 4 weeks. Treatment effects and toxicities were evaluated after ：2 cycles of chemotherapy. Results The overall response rate was 30.6 % （11/36）. The beneficial response was 63.9 % （：23/.36）. Median survival time was 6.6 moths and lyear survival rate was ：27.8%. The main toxicities were leucopenia and thrombocytopenia. All the toxicities were tolerable. Conclusion Gemcitabin is effective, safe and well-tolerable in the treatment of elderly patients with advanced NSCLC. It significantly improve the quality of life in patients witth NSCLC and prolong the survival time.
出处
《实用癌症杂志》
2007年第5期479-480,485,共3页
The Practical Journal of Cancer
关键词
非小细胞肺癌
老年患者
吉西他宾
化疗
Non-small cell lung cancer（ NSCLC ）
Elderly patients
Cemcitabine
Chemotherapy
